Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.
In this video, Urology Times® Co–Editor in Chief Michael S. Cookson, MD, MMHC, discusses 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Cookson is professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City.
The following abstracts were previewed:
1. LBA02-09 (Shore et al): EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer
2.LBA02-11 (Aggarwal et al): Updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19)
3. LBA03-03 (Mian et al): Infectious and non-infectious complications following prostate biopsy: a randomized clinical trial
4. MP29-01 (Saad et al): Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprivation therapy and docetaxel in ARASENS
5. MP29-02 (Shore et al): Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in the North American population from ARASENS